Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus platinum/pemetrexed first-line phase II study in malignant pleural mesothelioma
NL-OMON34616Phase 2Active, not recruiting
- Sponsor
- Zuyderland
- Start
- Dec 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab, cisplatin, carboplatin and pemetrexed in pleural mesothelioma (2 arms), sponsored by Zuyderland. Primary endpoint: Progression-free survival rate at 18 weeks. Started Dec 2011; status: active, not recruiting.
02
Drugs
cetuximabcisplatincarboplatinpemetrexed
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON34616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34616.